Content about NORTH WALES

May 14, 2013

Teva Health Systems has launched a generic injectable drug for small-cell lung cancer, the company said.

NORTH WALES, Pa. — Teva Health Systems has launched a generic injectable drug for small-cell lung cancer, the company said Tuesday.

Teva, a subsidiary of Teva Pharmaceuticals, itself a subsidiary of Israel-based Teva Pharmaceutical Industries, announced the launch of topotecan injection in the 1 mg-per-1 mL strength, in 4 mL, single-dose vials.

The drug is a generic version of GlaxoSmithKline's Hycamtin.

May 1, 2013

Teva introduces generic bronchospasm drug

Teva Pharmaceutical Industries has launched a generic inhaler used to treat bronchospasm, the company said.

NORTH WALES, Pa. — Teva Pharmaceutical Industries has launched a generic inhaler used to treat bronchospasm, the company said.

Teva announced the introduction of levalbuterol inhalation solution. The product is a generic version of Sunovion's Xopenex and is available in the 0.31 mg, 0.63 mg and 1.25 mg strengths.

Various versions of the drug had sales of $438.8 million in 2012, according to IMS Health.

April 8, 2013

Teva introduces generic painkiller

Teva Pharmaceutical Industries has launched a generic opioid medication for treating pain, the company said.

NORTH WALES, Pa. — Teva Pharmaceutical Industries has launched a generic opioid medication for treating pain, the company said.

Teva announced the introduction of oxymorphone hydrochloride tablets.

The drug is a generic version of Endo Pharmaceuticals' Opana and will be available in the 5 mg and 10 mg strengths in bottles of 100 tablets.

January 3, 2013

Teva announces inhaler with dose counter for bronchospasm

An inhaler for patients with bronchospasm that includes a dose counter has become available from Teva Respiratory, the company said Thursday.

NORTH WALES, Pa. — An inhaler for patients with bronchospasm that includes a dose counter has become available from Teva Respiratory, the company said Thursday.

The company, which is the branded respiratory division of Israeli drug maker Teva Pharmaceutical Industries, announced the available of ProAir HFA (i.e., albuterol sulfate), for patients aged 4 and older to prevent and treat bronchospasm with reversible obstructive airway disease and prevent exercise-induced bronchospasm. The inhaler received Food and Drug Administration approval in March 2012.